Project Grant R03AI190210
Award Date
8/1/25
Completion Date
7/31/27
Dollars Obligated
$161K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, provides $745,295 to the University of California, Irvine (UCI) to conduct research on deciphering the innate and adaptive immune responses to the tick-borne Rickettsia parkeri bacteria. The key objectives are to: 1) comprehensively identify R. parkeri virulence factors required for survival in macrophages, 2) reveal...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,663,244 project grant under CFDA 93.855, Allergy and Infectious Diseases Research, to President and Fellows of Harvard College (Harvard Medical School) on March 1, 2025. The project aims to characterize innate immune signaling pathways in the tick Ixodes scapularis, which is a vector for Lyme disease and other emerging infectious diseases. The research will combine cell culture-based methods with in vivo assays in...
This Project Grant award of $824,955.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to differentiate immune effector profiles and identify acute disease biomarkers in a guinea pig model of tick-transmitted spotted fever group rickettsiosis (SFR). The research aims to elucidate the immune response to spotted fever group rickettsiae and determine mechanisms underlying SFR development using a translational...
This Project Grant award of $440,000 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), supports research conducted by the University of Texas Medical Branch at Galveston (UTMB). The project aims to investigate the role of Rickettsia parkeri's cold shock protein A (CspA) as an exosome-specific RNA-binding protein that selectively enriches detrimental microRNAs (miR23a/27a/24/30b) in...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $518,099 to the University of Maryland, College Park to investigate a cross-species signaling system in tick immunity and development. The research aims to define how interactions between a novel tick protein (ISCDL) and the tick cell surface receptor DOME1 impact tick immune responses and development, either...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855), aims to identify diagnostic biomarkers for Typhus Group Rickettsioses (TGRs), including Epidemic Typhus and Murine Typhus. The $232,800 award to the University of Texas Medical Branch at Galveston (UTMB) will fund a 2-year research project to validate and quantify potential rickettsial protein biomarkers, and...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $710,000 to Georgia Southern University Research & Service Foundation Inc. over a 3-year period from June 2025 to May 2028. The project aims to develop comprehensive morphological and molecular tools to accurately identify Hyalomma tick species that are the principal vectors of the Crimean-Congo Hemorrhagic Fever (CCHF) virus. This will...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $423,106 over a 2-year period starting August 1, 2025 to characterize the roles of tick inhibitors of metalloproteases in the transmission of the Lyme disease agent by blacklegged ticks. The research aims to unveil the protease inhibition profiles of these tick proteins and elucidate their impacts on Lyme...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $463,698.00 to the University of Texas Medical Branch at Galveston (UTMB) for pre-clinical studies to repurpose FDA-approved adenosine A2A receptor antagonists for the treatment of lethal rickettsial infections. The research aims to determine the role of A2A receptor signaling in rickettsial infections,...
This $165,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of an improved transposon mutagenesis system for comprehensive genetic analysis of Borrelia burgdorferi, the bacterium that causes Lyme disease. The project aims to create a high-efficiency transposon insertional mutagenesis system and employ transposon sequencing techniques to conduct...